tranexamic acid has been researched along with Acrocephaly in 35 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Acrocephaly: Premature closing of the lambdoid and coronal sutures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pediatric craniosynostosis repair with cranial vault reconstructive surgery can be associated with significant blood loss." | 5.51 | Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair. ( Chung, E; Karlberg, HI, 2019) |
| "This multicenter international experience of pediatric craniofacial surgery reports no increase in seizures or thromboembolic events in those that received antifibrinolytics (tranexamic acid and epsilon-aminocaproic acid) versus those that did not." | 4.12 | Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group. ( Benzon, HA; Goobie, SM; King, MR; Nelson, O; Pérez-Pradilla, C; Staffa, SJ; Stricker, PA, 2022) |
| " There were no serious adverse events associated with the interventions in this study." | 3.11 | Safety and efficacy of aprotinin versus tranexamic acid for reducing absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery: a randomized, double-blind, three-arm controlled trial. ( Dabbagh Ohadi, MA; Ebrahim Soltani, A; Ebrahim Soltani, Z; Habibi, Z; Hanaei, S; Khademi, S; Maroufi, SF; Nejat, F; Tayebi Meybodi, K; Yaghmaei, B, 2022) |
| "Surgical correction of craniosynostosis can involve significant blood loss." | 3.01 | Optimizing Blood Loss and Management in Craniosynostosis Surgery: A Systematic Review of Outcomes Over the Last 40 Years. ( Coombs, DM; Knackstedt, R; Patel, N, 2023) |
| "Additional reduction of postoperative blood loss may further reduce exposure to allogeneic blood products." | 2.90 | Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial. ( D'Amore Lindholm, A; Fenger-Eriksen, C; Hvas, AM; Juul, N; Krogh, L; Nørholt, SE; Rasmussen, M; Tarpgaard, M; von Oettingen, G, 2019) |
| "The objective of this study was to conduct a population pharmacokinetic analysis and develop a model to predict an effective TXA dosing regimen for children with craniosynostosis undergoing cranial remodelling procedures." | 2.78 | Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery. ( Goobie, SM; Meier, PM; Pereira, LM; Samant, S; Sethna, NF; Soriano, SG; Zurakowski, D, 2013) |
| "Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding." | 2.76 | Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. ( Bigorre, M; Bringuier, S; Canaud, N; Capdevila, X; Dadure, C; Raux, O; Rochette, A; Sauter, M, 2011) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug, which has demonstrated a significant reduction in perioperative blood loss in many pediatric surgical procedures such as cardiac surgery and scoliosis surgery." | 2.61 | Reducing blood loss in pediatric craniosynostosis surgery by use of tranexamic acid. ( Eustache, G; Riffaud, L, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic which has been shown to decrease such a burden in particular surgeries." | 2.61 | Tranexamic Acid Decreases Blood Transfusion Burden in Open Craniosynostosis Surgery Without Operative Compromise. ( Daniels, DJ; Goyal, A; Lu, VM, 2019) |
| "Correction of craniosynostosis may require extensive surgical interventions with related intra and postoperative complications especially hemorrhage." | 2.53 | Surgical treatment of craniosynostosis in infants: open vs closed repair. ( Erb, TO; Meier, PM, 2016) |
| "Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding." | 2.49 | Tranexamic Acid reducing blood transfusion in children undergoing craniosynostosis surgery. ( Feng, G; Hu, J; Li, J; Li, Y; Luo, E; Song, G; Yang, P; Zhu, S, 2013) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has achieved significant reduction in perioperative blood loss and the quantity of blood transfused in many pediatric surgical procedures, without morbidity." | 1.72 | Importance of tranexamic acid in pediatric monosutural craniosynostosis surgery. ( Aillet, S; Aouaissia, S; Delahaye Larralde, S; Eustache, G; Nardi, N; Riffaud, L; Rousseau, C; Wodey, E, 2022) |
| "Nineteen patients had metopic synostosis, 11 had unicoronal synostosis, and 6 had bicoronal synostosis." | 1.62 | A protocol of situation-dependent transfusion, erythropoietin and tranexamic acid reduces transfusion in fronto-orbital advancement for metopic and coronal craniosynostosis. ( Chinnadurai, S; Escher, PJ; Kearney, SL; Kebriaei, MA; Linabery, AM; Petronio, JA; Tibesar, RJ; Tu, AD, 2021) |
| "Tranexamic acid use in craniosynostosis surgery has increased dramatically since 2010." | 1.56 | Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe? ( Bennett, WE; Cook, JA; Danforth, RM; Gerety, PA; Tholpady, SS, 2020) |
| "Pediatric craniosynostosis repair with cranial vault reconstructive surgery can be associated with significant blood loss." | 1.51 | Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair. ( Chung, E; Karlberg, HI, 2019) |
| "Blood loss during craniosynostosis surgery can be substantial, ranging from 20% to 500% of total circulating volume with a high associated risk of transfusion-related adverse events." | 1.48 | Perioperative Blood Loss and Transfusion in Craniosynostosis Surgery. ( Eccles, S; Hare, A; Miranda, BH; Ong, J; Park, C; Wormald, J, 2018) |
| "Consensus does not exist regarding the best dosage regimen for using tranexamic acid (TXA) for patients undergoing open calvarial vault remodeling in craniosynostosis surgery." | 1.48 | Craniosynostosis Surgery and the Impact of Tranexamic Acid Dosing. ( Bristol, R; Do, A; Kurnik, NM; Pflibsen, LR; Singh, DJ, 2018) |
| "Nine patients had craniosynostosis surgery without TXA (no-TXA group) and 16 patients received TXA (TXA group)." | 1.46 | Reducing Postoperative Bleeding After Craniosynostosis Repair Utilizing a Low-Dose Transexamic Acid Infusion Protocol. ( Andrews, BT; Hansen, JK; Lydick, AM; Wyatt, MM, 2017) |
| "Of a total of 259 patients with craniosynostosis, 187 had nonsyndromic single-suture involvement; 69 of these patients (36." | 1.43 | Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis. ( Diggs, B; Esmonde, N; Gries, H; Koh, J; Kuang, AA; Martin, DT; Schreiber, M; Selden, NR, 2016) |
| "Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis." | 1.42 | Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. ( Claiborne, JR; Couture, DE; Crantford, JC; David, LR; Ririe, DG; Thompson, JT; Wood, BC, 2015) |
| "A total of 33 children with metopic synostosis were operated on using standardized FOA, of which 16 patients (48." | 1.42 | The value of tranexamic acid during fronto-orbital advancement in isolated metopic craniosynostosis. ( Bodem, JP; Busch, CJ; Engel, M; Freudlsperger, C; Hoffmann, J; Horn, D; Mertens, C, 2015) |
| "Its use for craniosynostosis surgery warrants investigation." | 1.37 | Comparative analysis of tranexamic acid use in minimally invasive versus open craniosynostosis procedures. ( Istaphanous, G; Martin, D; Maugans, TA; Salisbury, S; Taylor, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.86) | 29.6817 |
| 2010's | 22 (62.86) | 24.3611 |
| 2020's | 12 (34.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zapata-Copete, JA | 1 |
| Gómez-Ospina, JC | 1 |
| García-Perdomo, HA | 1 |
| Caycedo, DJ | 1 |
| Eustache, G | 2 |
| Nardi, N | 1 |
| Rousseau, C | 1 |
| Aouaissia, S | 1 |
| Aillet, S | 1 |
| Delahaye Larralde, S | 1 |
| Wodey, E | 1 |
| Riffaud, L | 2 |
| Ebrahim Soltani, Z | 1 |
| Hanaei, S | 1 |
| Dabbagh Ohadi, MA | 1 |
| Maroufi, SF | 1 |
| Tayebi Meybodi, K | 1 |
| Khademi, S | 1 |
| Yaghmaei, B | 1 |
| Ebrahim Soltani, A | 1 |
| Nejat, F | 1 |
| Habibi, Z | 1 |
| Coombs, DM | 1 |
| Knackstedt, R | 1 |
| Patel, N | 1 |
| King, MR | 1 |
| Staffa, SJ | 2 |
| Stricker, PA | 1 |
| Pérez-Pradilla, C | 1 |
| Nelson, O | 1 |
| Benzon, HA | 1 |
| Goobie, SM | 4 |
| Ackerman, LL | 1 |
| Snider, AA | 1 |
| Ye, J | 1 |
| Fenger-Eriksen, C | 2 |
| Lindholm, AD | 1 |
| Krogh, L | 2 |
| Hell, T | 1 |
| Berger, M | 1 |
| Hermann, M | 1 |
| Fries, D | 1 |
| Juul, N | 2 |
| Rasmussen, M | 2 |
| Hvas, AM | 2 |
| Ongun, EA | 1 |
| Dursun, O | 1 |
| Kazan, MS | 1 |
| Escher, PJ | 2 |
| Tu, AD | 1 |
| Kearney, SL | 1 |
| Linabery, AM | 1 |
| Petronio, JA | 1 |
| Kebriaei, MA | 1 |
| Chinnadurai, S | 2 |
| Tibesar, RJ | 2 |
| Meara, JG | 2 |
| Proctor, MR | 2 |
| Tumolo, M | 1 |
| Cangemi, G | 1 |
| Disma, N | 1 |
| Danforth, RM | 1 |
| Cook, JA | 1 |
| Bennett, WE | 1 |
| Tholpady, SS | 1 |
| Gerety, PA | 1 |
| Borst, AJ | 1 |
| Bonfield, CM | 1 |
| Deenadayalan, PS | 1 |
| Le, CH | 1 |
| Xu, M | 1 |
| Sobey, JH | 1 |
| Reddy, SK | 1 |
| Hansen, JK | 1 |
| Lydick, AM | 1 |
| Wyatt, MM | 1 |
| Andrews, BT | 1 |
| Kurnik, NM | 2 |
| Pflibsen, LR | 2 |
| Bristol, RE | 1 |
| Singh, DJ | 2 |
| Park, C | 1 |
| Wormald, J | 1 |
| Miranda, BH | 1 |
| Ong, J | 1 |
| Hare, A | 1 |
| Eccles, S | 1 |
| Do, A | 1 |
| Bristol, R | 1 |
| Lu, VM | 1 |
| Goyal, A | 1 |
| Daniels, DJ | 1 |
| Chung, E | 1 |
| Karlberg, HI | 1 |
| D'Amore Lindholm, A | 1 |
| Nørholt, SE | 1 |
| von Oettingen, G | 1 |
| Tarpgaard, M | 1 |
| Tu, A | 1 |
| Kearney, S | 1 |
| Wheelwright, M | 1 |
| Petronio, J | 1 |
| Kebriaei, M | 1 |
| Sjoblom, MD | 1 |
| Busso, VO | 1 |
| Linscott, LL | 1 |
| Sadhasivam, S | 1 |
| Haas, T | 1 |
| Goobie, S | 1 |
| Spielmann, N | 1 |
| Weiss, M | 1 |
| Schmugge, M | 1 |
| Crantford, JC | 1 |
| Wood, BC | 1 |
| Claiborne, JR | 1 |
| Ririe, DG | 1 |
| Couture, DE | 1 |
| Thompson, JT | 1 |
| David, LR | 1 |
| Engel, M | 1 |
| Bodem, JP | 1 |
| Busch, CJ | 1 |
| Horn, D | 1 |
| Mertens, C | 1 |
| Hoffmann, J | 1 |
| Freudlsperger, C | 1 |
| Erb, TO | 1 |
| Meier, PM | 3 |
| Martin, DT | 1 |
| Gries, H | 1 |
| Esmonde, N | 1 |
| Diggs, B | 1 |
| Koh, J | 1 |
| Selden, NR | 1 |
| Schreiber, M | 1 |
| Kuang, AA | 1 |
| Holcomb, JB | 1 |
| Dadure, C | 1 |
| Sauter, M | 1 |
| Bringuier, S | 1 |
| Bigorre, M | 1 |
| Raux, O | 1 |
| Rochette, A | 1 |
| Canaud, N | 1 |
| Capdevila, X | 1 |
| Pereira, LM | 2 |
| McGowan, FX | 1 |
| Prescilla, RP | 1 |
| Scharp, LA | 1 |
| Rogers, GF | 1 |
| Soriano, SG | 2 |
| Zurakowski, D | 2 |
| Sethna, NF | 2 |
| Maugans, TA | 1 |
| Martin, D | 1 |
| Taylor, J | 1 |
| Salisbury, S | 1 |
| Istaphanous, G | 1 |
| Vergnaud, E | 1 |
| Vecchione, A | 1 |
| Blanot, S | 1 |
| di Rocco, F | 1 |
| Arnaud, E | 1 |
| Renier, D | 1 |
| Meyer, P | 1 |
| Song, G | 1 |
| Yang, P | 1 |
| Zhu, S | 1 |
| Luo, E | 1 |
| Feng, G | 1 |
| Hu, J | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Samant, S | 1 |
| Durán de la Fuente, P | 1 |
| García-Fernández, J | 1 |
| Pérez-López, C | 1 |
| Carceller, F | 1 |
| Gilsanz Rodríguez, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Population Pharmacokinetics/ Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery[NCT02188576] | Phase 4 | 66 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Does Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements? A Double-blinded Randomized Controlled Trial[NCT05024253] | Phase 3 | 48 participants (Anticipated) | Interventional | 2021-08-02 | Recruiting | ||
| Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| The Effectiveness Of Intravenous Tranexamic Acid (TXA) on Reducing Perioperative Blood Loss For Patients Undergoing Periacetabular Osteotomy (PAO): A Randomized Double Blind Placebo Controlled Trial[NCT03823417] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-31 | Withdrawn (stopped due to Investigators decided not to begin the study.) | ||
| The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?[NCT01813058] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119] | Phase 4 | 225 participants (Actual) | Interventional | 2016-03-15 | Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determine the efficacy ( as measured by blood loss and blood transfusion) of TXA in infants and children undergoing open craniofacial surgery with this lower dosage scheme. (NCT02188576)
Timeframe: perioperatively from the intraoperative period to 24 hours postoperatively
| Intervention | mL/kg (Mean) |
|---|---|
| High Dose TXA | 23.6 |
| Low Dose TXA | 21.3 |
Determine the plasma levels (in micrograms/mL) of TXA in infants and children undergoing open craniofacial surgery with this dosage scheme (NCT02188576)
Timeframe: up to 24h postoperatively
| Intervention | ug/mL (Mean) |
|---|---|
| High Dose TXA | 50.2 |
| Low Dose TXA | 29.6 |
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 2046 |
| Standard of Care/Control | 1596 |
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| High Dose/Study Group | 2 |
| Standard of Care/Control | 3 |
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 1259 |
| Standard of Care/Control | 935 |
Perioperative blood loss (during operation and for entire hospital admission) (NCT01813058)
Timeframe: perioperarively - during entire hospital admission
| Intervention | mL (Mean) |
|---|---|
| Placebo | 1031 |
| Tranexamic Acid | 836 |
6 reviews available for tranexamic acid and Acrocephaly
| Article | Year |
|---|---|
Role of tranexamic acid in craniosynostosis surgery: Systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; Prospective Studies; | 2022 |
Optimizing Blood Loss and Management in Craniosynostosis Surgery: A Systematic Review of Outcomes Over the Last 40 Years.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Humans; Tranexam | 2023 |
Reducing blood loss in pediatric craniosynostosis surgery by use of tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2019 |
Tranexamic Acid Decreases Blood Transfusion Burden in Open Craniosynostosis Surgery Without Operative Compromise.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Erythrocyte Transfusion; Humans; In | 2019 |
Surgical treatment of craniosynostosis in infants: open vs closed repair.
Topics: Anesthesia; Antifibrinolytic Agents; Craniosynostoses; Craniotomy; Hemodynamic Monitoring; Humans; I | 2016 |
Tranexamic Acid reducing blood transfusion in children undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Craniosynostoses; Humans; In | 2013 |
8 trials available for tranexamic acid and Acrocephaly
| Article | Year |
|---|---|
Safety and efficacy of aprotinin versus tranexamic acid for reducing absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery: a randomized, double-blind, three-arm controlled trial.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Child; Craniosyn | 2022 |
Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery.
Topics: Blood Coagulation; Child; Child, Preschool; Craniosynostoses; Factor XIII; Female; Fibrin Clot Lysis | 2020 |
High-dose versus low-dose tranexamic acid for paediatric craniosynostosis surgery: a double-blind randomised controlled non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostoses; Dose-Response Rel | 2020 |
Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial.
Topics: Anesthesia, General; Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostos | 2019 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschoo | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Child, Preschool; Craniosyn | 2011 |
Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Child, Preschool; Craniosynostoses; Dose-Response Relationship, Drug; Doubl | 2013 |
Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Child, Preschool; Craniosynostoses; Dose-Response Relationship, Drug; Doubl | 2013 |
Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Child, Preschool; Craniosynostoses; Dose-Response Relationship, Drug; Doubl | 2013 |
Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Child, Preschool; Craniosynostoses; Dose-Response Relationship, Drug; Doubl | 2013 |
[Usefulness of tranexamic acid in cranial remodeling surgery].
Topics: Anesthesia Recovery Period; Blood Component Transfusion; Blood Loss, Surgical; Craniosynostoses; Fem | 2003 |
21 other studies available for tranexamic acid and Acrocephaly
| Article | Year |
|---|---|
Importance of tranexamic acid in pediatric monosutural craniosynostosis surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; Infant; Retrospectiv | 2022 |
Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; I | 2022 |
Use of Subcutaneous Injection of Epinephrine and Triamcinolone with Tranexamic Acid Reduces Blood Loss, Transfusion Rates, and Length of Stay in Open Sagittal Craniosynostosis Repair.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Bupivacaine; Craniosynostoses; Hemoglobins; Humans; I | 2023 |
Tranexamic Acid Utilization in Craniosynostosis Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Craniotomy; Female; Humans; Infant, | 2020 |
A protocol of situation-dependent transfusion, erythropoietin and tranexamic acid reduces transfusion in fronto-orbital advancement for metopic and coronal craniosynostosis.
Topics: Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Erythropoietin; Humans; Infant; Retrospec | 2021 |
Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans; | 2020 |
ε-Aminocaproic acid versus tranexamic acid in children undergoing complex cranial vault reconstruction for repair of craniosynostosis.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; R | 2021 |
Reducing Postoperative Bleeding After Craniosynostosis Repair Utilizing a Low-Dose Transexamic Acid Infusion Protocol.
Topics: Adolescent; Antifibrinolytic Agents; Blood Transfusion; Child; Child, Preschool; Craniosynostoses; D | 2017 |
Tranexamic Acid Reduces Blood Loss in Craniosynostosis Surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Critical Care; H | 2017 |
Perioperative Blood Loss and Transfusion in Craniosynostosis Surgery.
Topics: Adolescent; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Craniotomy; Female; Hematocri | 2018 |
Craniosynostosis Surgery and the Impact of Tranexamic Acid Dosing.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Craniosynostoses; Dr | 2018 |
Ulnar Artery Thrombosis Following Tranexamic Acid Administration for Craniosynostosis Repair.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child, Preschool; Craniosynostoses; Female; Humans; T | 2019 |
Minimizing transfusion in sagittal craniosynostosis surgery: the Children's Hospital of Minnesota Protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child; Clinical Protocols; Cranios | 2019 |
Postoperative cerebral arterial thrombosis following cranial surgery in an infant.
Topics: Antifibrinolytic Agents; Cerebral Angiography; Craniosynostoses; Craniotomy; Humans; Infant; Intracr | 2013 |
Improvements in patient blood management for pediatric craniosynostosis surgery using a ROTEM(®) -assisted strategy - feasibility and costs.
Topics: Algorithms; Blood Cell Count; Blood Gas Analysis; Blood Transfusion; Craniosynostoses; Feasibility S | 2014 |
Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child, Preschool; Cohort Studies; | 2015 |
The value of tranexamic acid during fronto-orbital advancement in isolated metopic craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans; | 2015 |
Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Hemorrhage; Humans; Infant; Postope | 2016 |
Tranexamic acid in elective craniosynostosis surgery: it works, but how?
Topics: Antifibrinolytic Agents; Craniosynostoses; Elective Surgical Procedures; Humans; Tranexamic Acid | 2011 |
Comparative analysis of tranexamic acid use in minimally invasive versus open craniosynostosis procedures.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Chi-Square Distribution; Child; Craniosynostoses; Fem | 2011 |
Reducing blood losses and transfusion requirements in craniosynostosis surgery: an endless quest?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Elective Surgica | 2012 |